This stock is no longer traded. It was delisted on September 3, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel biologic therapies for inflammatory and immunology conditions. Its programs target diseases such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease, areas where current treatment options can leave important unmet needs. The company centers its research on antibody-based medicines designed to improve durability, dosing convenience, and therapeutic performance through advanced engineering. Apogee Therapeutics Inc. also explores combination and monotherapy approaches across dermatology, respiratory, and gastroenterology-related indications. Headquartered in Waltham, Massachusetts and founded in 2022, the company plays a role in the biopharmaceutical market by advancing specialized treatments for patients with chronic immune-mediated disorders.
WebsiteOne Letterman Drive
San Francisco, CA, 94129-1492
United States
The latest articles about APGE.
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]
Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.
Summary of Jun 24's posts. Generated by AI.
Summary of Jun 22's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Investors talking about APGE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.